The moat isn't on your wrist
In January, Whoop signed Scuderia Ferrari HP as its newest sports partnership. In March, Oura acquired a gesture-recognition startup in Helsinki. By May, both had moved on from devices: Whoop opened a UAE office on the back of a $75M Mubadala cheque, Oura turned its app into a place you can get a birth-control prescription. Two completely different stages, one identical strategy: the wristband and the ring are no longer the product. They are the marketing for the product.
The product is the pipe into your medical record.
👉 The most valuable thing Whoop and Oura bought in 2026 isn't a brand, a sport, or a sensor. It is data access. The wrist-and-finger hardware is now a commodity, and the real moat belongs to whoever owns the cleanest pipe between consumer wearables and clinical systems.
This shift is happening loudly and quietly at the same time. Loudly, because the sports deals are everywhere; from Ferrari to Premier Padel to the LA28 Games. Quietly, because the partnerships that actually move the strategy live on the press-release pages nobody scrolls to.
Oura: become the plumbing
Oura's 2026 reads like a textbook platform play. In March it acquired Doublepoint Technologies for gesture recognition. In April it acquired Galen AI, a Stanford-and-YC company that connects to medical records across more than 800 healthcare systems in the US, UK, and Canada via Apple HealthKit and FHIR. That second move is the one to highlight. The ring vendor just bought a clinical-data-integration company.
The partnership list sharpens the picture. Fullscript wires Oura data into the practitioner-side workflow alongside lab results. Mira plugs in lab-grade hormone tests. Vida Health adds continuous metabolic care. On May 1, Twentyeight Health joined the stack: US members can now connect with a licensed clinician inside the Oura App and walk away with a hormonal birth-control prescription. The ring just became a point-of-care channel for new prescriptions, not only a monitoring device. In May, the Department of Health of Abu Dhabi also signed a long-term joint research deal on continuous wearable data for preventive health, starting with women's health and cardiometabolic risk.
⚽️ In parallel, Oura kept the loud lane moving: a long-term U.S. Soccer partnership naming the ring Official Wearable of U.S. Soccer, a five-year USTA / U.S. Open deal making it the tournament's first wearable partner, and the path to LA28.
The Olympic and U.S. Soccer announcements bought the headlines. The Galen AI + Fullscript + Mira stack is what they bought the headlines to fund.
Whoop: become the care provider
Whoop went the opposite way. No M&A, but a $575M Series G (around €530M) at a $10.1B valuation, led by Collaborative Fund with Mubadala, Qatar Investment Authority, Abbott, and Mayo Clinic participating. Those are not sports investors. Forbes asked the obvious question about whether the wellness brand can cross over into health, and the answer landed in April: WHOOP Physician Services PC was selected for the first cohort of the CMS Innovation Center ACCESS programme, which will reimburse technology-enabled Medicare care from summer 2026. For the first time, a wristband company will get paid by US Medicare for monitoring patients between visits.
🪖 Two deals around it fill in the picture. In late April, MIT Lincoln Laboratory awarded Whoop a contract for the U.S. Navy's Command Readiness, Endurance and Watchstanding (CREW) programme, the first major military integration on the wrist; that contract followed the cancellation of an approximately $96M Department of Defense ring contract previously awarded to Oura. Two weeks later, Mubadala layered a separate $75M strategic partnership on top of its Series G position: a dedicated UAE office, full Arabic localisation of the app, an Advanced Labs expansion that makes Abu Dhabi the first international market with Whoop's full US biomarker testing experience, and a co-branded WHOOP-Mubadala Health Research Initiative. The same playbook run twice in a fortnight: government anchor on one side, sovereign-capital anchor on the other.
May 2026 added the rest of the stack: an EHR-integration deal with HealthEx so members can sync diagnoses, medications, and procedures into the Whoop app; in-app clinician video visits launching this summer; Quest Diagnostics for labs; an FDA-cleared ECG and blood-pressure readings already shipping. As Longevity.Technology framed it, Whoop is moving into clinical care while Fitbit quietly rebrands into Google Health.
Same destination, mirror-image bets
Both companies are walking from "wearable brand" to "health platform" down opposite paths. Oura bets that the device stays consumer and the data becomes clinically meaningful through other people who already deliver care. Whoop bets that the device is the front door to a regulated healthcare business it operates itself.
- Move: Oura buys and integrates; Whoop capitalises and operates.
- Critical asset: Galen AI (Oura's clinical-record pipe) vs CMS ACCESS reimbursement (Whoop's).
- Care delivery: Oura partners with practitioners (Twentyeight Health Rx in-app); Whoop becomes the practitioner.
- Government anchor: Oura's DoD ring contract cancelled; Whoop won U.S. Navy CREW via MIT Lincoln Lab.
- Gulf anchor: Oura signed Abu Dhabi DoH; Whoop closed Mubadala $75M + UAE office, Qatar Foundation, Zain Kuwait.
- Brand top-line: Oura with Olympics, USTA, U.S. Soccer; Whoop with Ferrari, Padel, Boston Red Sox.
The Gulf is the third strategic pole in this category alongside the US and EU. Sovereign capital, regulatory daylight, and a deliberate test-bed posture make Abu Dhabi and Doha attractive to both companies for the same reason; in fact, Abu Dhabi just opened a real-world longevity test lab the same week the Forbes piece dropped. Whoop alone closed three Gulf deals inside twelve days in May: Mubadala in Abu Dhabi, Qatar Foundation at Doha's Education City, and a Zain Kuwait carrier-bundle that puts the wearable on monthly instalments through a 5G telco. That is not sponsorship; that is a regional go-to-market on fast-forward.
⚠️ One wobble worth flagging on Oura's side. As the company industrialises the back end, parts of its consumer base are pushing back in public. Mid-May threads on r/ouraring and a BGR piece surfaced concerns about Oura's Palantir FedStart hosting and its broader DoD relationships; Oura denies selling user data, but the gap between 'wellness ring on my finger' and 'platform handling federal contracts' is widening in the consumer mind. The clinical-pipe thesis assumes consumer trust holds while the infrastructure gets industrialised. If consumers force a fork between 'wellness Oura' and 'clinical Oura', the moat fragments before it crystallises.
The watch list, and the European gap
Three pieces of plumbing matter more than anything else: Galen AI's clinical-record integration, HealthEx's EHR sync, and the new prescribing rails that turn the app itself into a point of care (Twentyeight Health on Oura, on-demand clinicians on Whoop). Whoever cracks frictionless EHR, lab, and prescribing flow into the consumer-wearable layer at scale will own the next five years of this category. Worth's "Biohacking Economy" piece is right that a parallel health system is being assembled outside of insurance; the question is who owns the rail it runs on.
🇪🇺 That brings the broader European point. CMS ACCESS is US-specific. There is no European equivalent of "Medicare will reimburse for AI-monitored care between visits." For European insurers, for hospital groups, for regional regulators, that gap is either a cliff or an opening. Whoever defines the European reimbursement pathway first will set the terms before the US-built moat reaches the EU clinic.
The next five years of consumer health won't be won by the prettiest device. They will be won by whoever owns the cleanest pipe between your wrist and your medical record.
👀 Next experiment: pick a wearable brand active in your market and map their last twelve months of partnerships and acquisitions on one page. If the list is sport, brand, and lifestyle, they are still selling devices. If the list is EHR, labs, payers, and reimbursement, they are building infrastructure. Decide which side you want to integrate with before the choice is made for you.
💥 May this inspire you to look past the sports deal and read the partnership page.